Contact Information: Contact: The Global Consulting Group Rachel Levine T: (646) 284-9439 E: Email Contact
Cleveland BioLabs to Present at Friedman Billings Ramsey 2007 Growth Conference
| Source: Cleveland BioLabs, Inc.
CLEVELAND, OH -- (MARKET WIRE) -- May 23, 2007 -- Cleveland BioLabs, Inc. (NASDAQ : CBLI ) (BOST : CFB ) today announced that the Company is scheduled to present at the
Friedman, Billings, Ramsey & Co., Inc. 2007 Growth Conference to be held at
The Grand Hyatt New York in New York City, May 30-31.
Michael Fonstein, Ph.D., President and Chief Executive Officer of Cleveland
BioLabs, will give a presentation on the Company followed by a question and
answer session on May 30, at 8:15 a.m. EDT. The presentation will be
broadcast live over the Internet and archived for three months. Interested
parties may tune in to the live presentation by visiting the Company's
website at: www.cbiolabs.com.
Cleveland BioLabs recently announced the results of a study of the efficacy
of Protectan CBLB612, one of its radiation protectors, in an animal bone
marrow stem cell transplantation model. Peripheral blood from
CBLB612-treated donors rescued 100% of lethally irradiated mice from bone
marrow deficiency. The rescuing effect of the peripheral blood of the
treated mice was equivalent to that of conventional bone marrow
transplantation.
The Company has two lead compounds in late stages of development. Curaxin
CBLC102 is an orally administered small molecule designed to kill tumor
cells by simultaneously targeting two key regulators of apoptosis. The
Company has an ongoing Phase II trial with CBLC102 in hormone refractory
prostate cancer.
Cleveland BioLabs' other lead compound, Protectan CBLB502, is a modified
protein of a microbe that protects cells from regulated cell death. The
Company recently submitted CBLB502 to the Department of Defense in response
to a Request for Proposal (RFP) for medical radiation countermeasures to
treat gastrointestinal effects of acute radiation syndrome. The RFP award
would provide funding for development of the countermeasure through FDA
approval, as well as a commitment to purchase up to 500,000 doses,
thereafter.
Cleveland BioLabs management will be available for meetings with investors
on May 30 and 31 in New York.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging its proprietary discoveries about programmed cell death to treat
cancer and protect normal tissues from exposure to radiation and other
stresses. The Company has strategic partnerships with the Cleveland Clinic
Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the
Armed Forces Research Radiobiology Institute. To learn more about
Cleveland BioLabs, Inc., please visit the company's website at
http://www.cbiolabs.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of
this press release, and involve certain risks and uncertainties. Our actual
results could differ materially from those anticipated in these
forward-looking statements as a result of various factors. Some of the
factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include the
"Risk Factors" described in our Registration Statement on Form SB-2/A filed
with the Securities and Exchange Commission on September 8, 2006.